EMVision Raises AU$2 Million Through Oversubscribed Share Purchase Plan

EMVision Medical Devices Ltd (ASX: EMV) has successfully completed its Share Purchase Plan (SPP), raising approximately AU$2 million following strong shareholder demand. The SPP, announced on 17 September 2025, was heavily oversubscribed, leading to scale-backs and allocations prioritised for early applicants.

Together with the recent AU$12 million placement, EMVision has raised a total of AU$14 million, strengthening its financial position to advance key milestones, including the pivotal trial readout, FDA submission, and initial commercialisation of the emu™ device.

Funds will also support the First Responder Program, covering clinical trials, production readiness, and regulatory preparation. The company highlighted that the overwhelming support reflects investor confidence in its mission to transform stroke and neurological emergency diagnostics through portable, non-invasive imaging technology.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com